A8736-5mg | THZ531 [1702809-17-3] Clinisciences

THZ531 is a first-in-class CDK12 and CDK13 covalent inhibitor with IC50 values of 158 nM and 69 nM, respectively [1].

Complexes containing CDK12 and CDK13 regulate transcriptional elongation as well as processes, including mRNA splicing and 3’-end RNA processing. Loss of CDK12 and CDK13, or of their cofactor cyclin K, impedes both Pol II processivity and RNA processing [1].

THZ531 is an irreversible CDK12 and CDK13 covalent inhibitor. THZ531 potently inhibited CDK12 and CDK13 with IC50 values of 158 nM and 69 nM, whereas inhibition of CDK7 and CDK9 was more than 50-fold weaker, with IC50s of 8.5 μM and 10.5 μM, respectively. In Jurkat cells, THZ531 irreversibly reduced cell proliferation with IC50 of 50 nM. THZ531 induced apoptosis in a dose- and time-dependent way. THZ531 also reduced Pol II C-terminal domain (CTD) Ser2 phosphorylation, a mark of active transcriptional elongation, resulted in the loss of key super-enhancer-associated transcription factor genes and DNA damage response (DDR) genes expression [1].

Reference:

1.Zhang T, Kwiatkowski N, Olson CM, et al. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol. 2016 Oct;12(10):876-84.

1. Peuget S, Zhu J, et al. "Thermal proteome profiling identifies oxidative-dependent inhibition of the transcription of major oncogenes as a new therapeutic mechanism for select anticancer compounds." Cancer Res. 2020;canres.2069.2019. PMID:32019870
2. Wang C, Vegna S, et al. "Inducing and exploiting vulnerabilities for the treatment of liver cancer." Nature. 2019 Oct 2. PMID:31578521
3. Wang C, Wang H, et al. "CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma." Gut. 2019 Sep 13. pii: gutjnl-2019-318506. PMID:31519701

Physical Appearance	A solid
Storage	Store at -20°C
M.Wt	558.07
Cas No.	1702809-17-3
Formula	C₃₀H₃₂ClN₇O₂
Solubility	≥55.8 mg/mL in DMSO; insoluble in H2O; ≥4.9 mg/mL in EtOH
Chemical Name	(R,E)-N-(4-(3-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)piperidine-1-carbonyl)phenyl)-4-(dimethylamino)but-2-enamide
SDF	Download SDF
Canonical SMILES	ClC1=CN=C(N[C@H]2CN(C(C3=CC=C(NC(/C=C/CN(C)C)=O)C=C3)=O)CCC2)N=C1C4=CNC5=C4C=CC=C5
Shipping Condition	Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips	We do not recommend long-term storage for the solution, please use it up soon.

Kinase experiment [1]:
Binding assays	Radioactive kinase activity measurements were performed at a concentration of 0.2 μM CDK–cyclin complex. Typically, 35 μl reaction volumes of 0.2 μM active kinase were equilibrated in kinase buffer (40 mM Hepes (pH 7.6)), 34 mM NaCl, 34 mM KCl, 10 mM MgCl2, 5% glycerol, and 1× PhosSTOP. Cold ATP to a final concentration of 200 μM and 3 μCi [γ-32P]ATP and 50 μM of a substrate peptide containing five phosphorylation sites were added and the reaction mixture incubated for 30 min at 30 °C at 350 rpm in a thermomixer. Reactions were stopped by adding EDTA to a final concentration of 50 mM. Aliquots of 15 μl each were spotted onto paper squares using the Optitran BA-S85 reinforced membrane. Paper squares were washed three times for 5 min with 0.75% (v/v) phosphoric acid, with at least 5 ml washing solution per paper. Radioactivity was counted in a Beckman Scintillation Counter (Beckman Coulter) for 1 min. Compounds THZ531 was added at varying concentrations to 0.2 μM CDK–cyclin complex and incubated for varying times from 1 to 540 min at 30 °C and 350 rpm before ATP and substrate were added to the reaction mix.
Cell experiment [1]:
Cell lines	Jurkat cells
Preparation method	This compound is soluble in DMSO. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.
Reacting condition	50-1200 nM, 6 h
Applications	THZ531 treatment led to a dramatic and irreversible decrease in Jurkat cell proliferation with an IC50 of 50 nM. Treatment with escalating doses of THZ531 displayed a dose- and time-dependent increase in the number of cells exhibiting sub-G1 content. Higher doses of THZ531 led to a pronounced annexin V signal, with 30–40% annexin-V-stained cells by 72 h. THZ531 selectively reduced Ser2 phosphorylation levels without appreciable effect on CTD pSer5 or pSer7 levels. Treatment with 50 nM THZ531 resulted in the loss of expression of a small subset of genes.
Other notes	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.
References: [1]. Zhang T, Kwiatkowski N, Olson C M, et al. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors[J]. Nature chemical biology, 2016.

Purity = 98.39%

Chemical structure

THZ531 [1702809-17-3]

Référence A8736-5mg

Contactez votre distributeur local :

Marque : ApexBio Technology

Contactez votre distributeur local :

Background

Product Citation

Chemical Properties

Protocol

Quality Control

Chemical structure

Vous serez peut-être également intéressé par les produits suivants :